"Valmet operates at the heart of two global transformations: advancing circularity and unlocking resource efficiency. Our strategy, Lead the Way, sharpens our focus on these themes with a clear purpose: Transforming industries towards a regenerative tomorrow.
With 35–50% market share in key biomaterial process technologies, Valmet has built one of the largest installed bases in the industry — a structural advantage that drives recurring revenues and long-term customer relationships. As one of the leading service partners globally, we support customers across the lifecycle from initial delivery through decades of operation.
We see structural growth opportunities in both segments. In Biomaterial Solutions and Services, we aim to double our organic services growth to 8% and raise market share to 25% by 2030. In Process Performance Solutions, we deliver mission-critical technologies that improve resource efficiency, reduce emissions, and support customers’ core operations. Our target is to grow organically at more than twice the market rate.
These ambitions are backed by strong fundamentals, a streamlined operating model, and a clear 2030 financial framework: 5% organic growth, 15% comparable EBITA margin, and 20% ROCE.
Read more about the reasons to invest in Valmet in our comprehensive investor website and remember to subscribe to our IR newsletter and follow us on social media platform X @ValmetIR." You can read more about Valmet as a company here.
- Pekka Rouhiainen, VP, Investor Relations

Key figures from 2025
€ 5.2
Billion in net sales
€ 5.2
Billion in orders received
11.9%
Comparable EBITA margin
€ 1.82
Adjusted earnings per share
Stock exchange releases
- Feb 6, 2026Notice Convening the Annual General Meeting of Valmet Oyj
- Feb 6, 2026Valmet’s Financial Statements Review January 1 – December 31, 2025: ‘Lead the Way’ strategy delivered first results: Comparable EBITA margin increased to 11.9 percent in 2025
- Dec 19, 2025The Shareholders' Nomination Board of Valmet proposes the composition and remuneration of the Board of Directors as well as amending the charter of the Shareholders’ Nomination Board
- Dec 17, 2025Valmet establishes new share-based incentive plans for key employees
- Dec 16, 2025Change in Valmet Oyj’s holding of treasury shares
Press releases
- Feb 12, 2026Valmet increases Yusen Groups’s production capacity for high-quality tissue with three additional IntelliTissue machines
- Feb 6, 2026Valmet to deliver advanced process analytical solutions to Dow’s Path2Zero project, supporting net-zero emissions goals for ethylene cracking
- Jan 22, 2026Valmet’s Beyond Circularity program concludes: Ecosystem‑driven collaboration accelerates green transition
- Jan 14, 2026Valmet will support Faderco Group doubling tissue production capacity with a third Advantage DCT tissue line
- Jan 13, 2026Publishing of Valmet's Financial Statements Review 2025 on February 6, 2026
Contact Valmet Investor Relations at ir(at)valmet.com
VP, Investor Relations
Phone: +358 10 672 0020
E-mail: pekka.rouhiainen(at)valmet.com